What does ASYLIA DIAGNOSTICS do?

ASYLIA DIAGNOSTICS is a research organisation in Leuven. Private Limited, started on 22 August 2019, 1 establishment.

What is the address of ASYLIA DIAGNOSTICS?

The registered office of ASYLIA DIAGNOSTICS is located at Philipssite 5 box 1, 3001 Leuven.

Is ASYLIA DIAGNOSTICS still active?

Yes. According to the CBE (29 October 2026) ASYLIA DIAGNOSTICS is active, legal situation “Normale toestand”, started on 22 August 2019.

Is ASYLIA DIAGNOSTICS registered on Peppol?

Yes, ASYLIA DIAGNOSTICS is registered on the Peppol network with ID 0208:0732783629.

What is the enterprise number of ASYLIA DIAGNOSTICS?

The enterprise number of ASYLIA DIAGNOSTICS is BE0732783629.

When was ASYLIA DIAGNOSTICS founded?

ASYLIA DIAGNOSTICS was founded on 22 August 2019.

Who are the directors of ASYLIA DIAGNOSTICS?

According to the 2024 annual accounts, the directors of ASYLIA DIAGNOSTICS are: Andrey KHMELEVSKIY, PHARMALEGAL BV, Anna KOSTIKOVA.

Is ASYLIA DIAGNOSTICS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 August 2019; 4 annual accounts filed, latest fiscal year 2024; 3 directors known from the annual account.

How much profit did ASYLIA DIAGNOSTICS make in 2024?

ASYLIA DIAGNOSTICS recorded a loss after taxes of € 183,907 in financial year 2024.

What is the revenue of ASYLIA DIAGNOSTICS?

As a small company, ASYLIA DIAGNOSTICS is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € -125,098.

ASYLIA DIAGNOSTICS (Private Limited) - Leuven

Dossier ASYLIA DIAGNOSTICS, printed on 29 October 2026 from databakkes.be/en/0732783629/asylia-diagnostics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2023 and 2024.
Busy address KBO

86 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2024

ASYLIA DIAGNOSTICS from Leuven, company number BE0732783629, closed financial year 2024 with a result of € -183,907 after tax. For that financial year ASYLIA DIAGNOSTICS recorded a gross margin of € -125,098 and equity of € 109,193. Compared with financial year 2023, the result moved from € -155,958 to € -183,907. The company made a loss. The buffer shrank hard: equity is 63 % below last year. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 4, 2025.

What it is worth Shrank hard

€ 109,193

▼ 63% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -183,907

▼ 18 % more loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 22,889

▼ 53% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -470,728.

People and assets in 2024

Wage cost

€ 103

▼ 3% vs 2023

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 955

▼ 65% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt

€ 405,000

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 4,351

▲ € 3,920 vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 1,949

▼ 85% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ -126,758 Gross margin 2021: € -126,758 First fiscal year in the series	€ 163,378 Gross margin 2022: € 163,378 ▲ € 290,136 vs 2021 (€ -126,758) Favourable step	€ -63,871 Gross margin 2023: € -63,871 ▼ € 227,249 vs 2022 (€ 163,378) Unfavourable step	€ -125,098 Gross margin 2024: € -125,098 ▼ € 61,227 vs 2023 (€ -63,871) Unfavourable step	▼ € 61,227
Profit after taxes	€ -141,494 Profit after taxes 2021: € -141,494 First fiscal year in the series	€ 75,602 Profit after taxes 2022: € 75,602 ▲ € 217,097 vs 2021 (€ -141,494) Favourable step	€ -155,958 Profit after taxes 2023: € -155,958 ▼ € 231,561 vs 2022 (€ 75,602) Unfavourable step	€ -183,907 Profit after taxes 2024: € -183,907 ▼ € 27,949 vs 2023 (€ -155,958) Unfavourable step	▼ € 27,949
Equity	€ 118,456 Equity 2021: € 118,456 First fiscal year in the series	€ 449,058 Equity 2022: € 449,058 ▲ 279% vs 2021 (€ 118,456) Favourable step	€ 293,100 Equity 2023: € 293,100 ▼ 35% vs 2022 (€ 449,058) Unfavourable step	€ 109,193 Equity 2024: € 109,193 ▼ 63% vs 2023 (€ 293,100) Unfavourable step	▼ 63%
Total debts	€ 603,410 Total debts 2021: € 603,410 First fiscal year in the series	€ 474,648 Total debts 2022: € 474,648 ▼ 21% vs 2021 (€ 603,410) Favourable step	€ 425,290 Total debts 2023: € 425,290 ▼ 10% vs 2022 (€ 474,648) Favourable step	€ 442,897 Total debts 2024: € 442,897 ▲ 4% vs 2023 (€ 425,290) Unfavourable step	▲ 4%
Cash	€ 494,316 Cash 2021: € 494,316 First fiscal year in the series	€ 151,939 Cash 2022: € 151,939 ▼ 69% vs 2021 (€ 494,316) Unfavourable step	€ 48,461 Cash 2023: € 48,461 ▼ 68% vs 2022 (€ 151,939) Unfavourable step	€ 22,889 Cash 2024: € 22,889 ▼ 53% vs 2023 (€ 48,461) Unfavourable step	▼ 53%
Retained profit	€ -206,465 Retained profit 2021: € -206,465 First fiscal year in the series	€ -130,863 Retained profit 2022: € -130,863 ▲ € 75,602 vs 2021 (€ -206,465) Favourable step	€ -286,821 Retained profit 2023: € -286,821 ▼ € 155,958 vs 2022 (€ -130,863) Unfavourable step	€ -470,728 Retained profit 2024: € -470,728 ▼ € 183,907 vs 2023 (€ -286,821) Unfavourable step	▼ € 183,907
Bank debt	€ 455,000 Bank debt 2021: € 455,000 First fiscal year in the series	€ 455,000 Bank debt 2022: € 455,000 Unchanged (€ 455,000) Unchanged	€ 405,000 Bank debt 2023: € 405,000 ▼ 11% vs 2022 (€ 455,000) Favourable step	€ 405,000 Bank debt 2024: € 405,000 Unchanged (€ 405,000) Unchanged
Balance sheet total	€ 721,866 Balance sheet total 2021: € 721,866 First fiscal year in the series	€ 923,707 Balance sheet total 2022: € 923,707 ▲ 28% vs 2021 (€ 721,866) Unchanged	€ 718,390 Balance sheet total 2023: € 718,390 ▼ 22% vs 2022 (€ 923,707) Unchanged	€ 552,090 Balance sheet total 2024: € 552,090 ▼ 23% vs 2023 (€ 718,390) Unchanged	▼ 23%

Key figures of ASYLIA DIAGNOSTICS, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to ASYLIA DIAGNOSTICS?

What happened at ASYLIA DIAGNOSTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 4, 2025 New annual accounts for financial year 2024: loss of € 183,907. Source: NBB ↗
Aug 22, 2019 New establishment in Leuven. KBO
2019 Andrey KHMELEVSKIY became a director. NBB
2019 PHARMALEGAL BV became a director. NBB
2019 Anna KOSTIKOVA became a director. NBB
Aug 22, 2019 Start of the company according to the CBE. KBO

In short

From € 141,494 loss in 2021 to € 183,907 loss in 2024.

Best year ever: 2022, with € 75,602 profit.

Original PDFs at the National Bank ↗

Management

Andrey KHMELEVSKIY PHARMALEGAL BV Anna KOSTIKOVA

ASYLIA DIAGNOSTICS

ZORGPUNT

Lynxcare Clinical Informatics

Curaevia

Behind ASYLIA DIAGNOSTICS are Andrey KHMELEVSKIY, PHARMALEGAL BV and Anna KOSTIKOVA. PHARMALEGAL BV is also behind ZORGPUNT, Lynxcare Clinical Informatics, Curaevia, Thuiszorg Cooperatie and PharmaBXL.

Directors

According to the 2024 annual accounts

Andrey KHMELEVSKIY

Director

since 2019

PHARMALEGAL BV

Director · represented by DE FEU Georges

Also active at: ZORGPUNT, Lynxcare Clinical Informatics, Curaevia, Thuiszorg Cooperatie, PharmaBXL, AMPHIKTION

since 2019

Anna KOSTIKOVA

Director

since 2019

Establishments

Establishment units

Physical locations of this company

Registered office

Philipssite 5 box 1

3001 Leuven

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 86 companies are registered at this address.

All companies at this address →

Norgine

€ 19.1 million revenue · 2024

DRAKA BELGIUM

€ 3.4 million revenue · 2025

LOFMA

€ 1.8 million gross margin · 2025

G.I.M. - GEOGRAPHIC INFORMATION MANAGEMENT

€ 7.1 million revenue · 2025

ADVOCATENASSOCIATIE NELISSEN GRADE

€ 477,864 gross margin · 2025

+81 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0732.783.629

VAT number

BE 0732.783.629

Registered office

Philipssite 5 bus 1, 3001 Leuven

Names & denominations

ASYLIA DIAGNOSTICS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

22 August 2019

Peppol

Active · Active since 16 Dec 2025

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

ASYLIA DIAGNOSTICS

Warning lights

Financials

What happened to ASYLIA DIAGNOSTICS?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions